Subsequent Events (Tables)

9 Months Ended

Sep. 30, 2022

Subsequent Events [Abstract]

Schedule of remaining potential milestone payments

Under the terms of the GSK License Agreement, the Company is entitled to receive an upfront payment of $66.0 million for GSK to secure rights to the medicine. Remaining potential payments are milestone and royalty based, and are as follows (in millions):

Event	Milestone payments (up to)
Delivery of Phase 3 program	$150.0
Total commercial milestone payments based on first sale (US/EU)	$150.0
Total potential sales milestone payments	$225.0
Royalties	Low-single digit to low-double digit (if sales exceed $1.0 billion) tiered royalties on net product sales.